huIL-18 MAAEPVEDNCINFVAMKFIDNT-LYFIAED---DEN---LESDYFGKLE---S--K
huIL-1F7b M----------SFVG----ENSGVKMGSEDWEKDEPQCCLEDPAVSPLEPGPSLPA
huIL-18 LS-V-----IRNLN-------DQ---VLFIDQGN----------RP-LF----EDM
huIL-1F7b MNFVHTSPKVKNLNPKKFSIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSL
huIL-18 TDSDCRDNAPRTIFI-IS-----MY--KD---SQPRGMAVTISVKCEKISTLSCEN
huIL-1F7b SSASAEKGSP--ILLGVSKGEFCLYCDKDKGQSHP-----SLQLKKEKLMKLAAQ-
huIL-18 KIISFKEMNPPDNIKDTKSDIIFFQRSVPGHDNKMQFESSSYEGYFL--ACE-KE-
huIL-1F7b -----KE--------SARRPFIFYRAQV-GSWN-M-LESAAHPGWFICTSCNCNEP
huIL-18 ---RDLFKLILKKEDELGDRSIMFTVQ---------NE--D
huIL-1F7b VGVTDKF------ENR---KHIEFSFQPVCKAEMSPSEVSD

Figure 1


2 A
100000
10000
1000
100
10
1
IFNγ (pg/ml)
control
mat IL-1F7b
pro IL-1F7b
IL-18
NKO
KG-1
whole blood
PBMC
2 B
140
120
100
80
60
40
20
0
IFNγ (% of positive control)
pro IL-1F7b
mat IL-F7b
0
250
500
750
1000
IL-1F7b (ng/ml)

Figure 2


3 A
+ + + + IL-18Rα:D3
+ pro IL-1F7b
+ mat IL-1F7b
MW (kDa) + + + BS3
45
30
20.1
IL-1F7b+IL-18Rα:D3
IL-18Rα:D3 dimer
IL-18Rα:D3 monomer
3 B
+ IL-18Rα
+ IL-18Rβ
MW (kDa)
Φ
pro IL-1F7b
mat IL-1F7b
IL-18
210
97
66
46
IL-18+IL-18Rα/β

Figure 3


IL-18BP - + - + - +
control
4 A
97
66
45
4B
97
66
45
pro IL-1F7b
mat IL-1F7b
IL-18
BP ø BS3
BP + BS3

Figure 4


5A
100
80
60
40
20
0
IFNγ % of control
***
***
only IL-18BP
with mat IL-1F7b
1
10
100
IL-18BP (ng/ml)
5B
100
80
60
40
20
0
IFNγ % of control
only IL-18BP
with pro IL-1F7b
1
10
100
IL-18BP (ng/ml)

Figure 5



Figure 6